A5093192864- Cystic Fibrosis Research Advances
- COVID-19 epidemiological studies
- Tracheal and airway disorders
- Pediatric health and respiratory diseases
- COVID-19 Pandemic Impacts
- Immune responses and vaccinations
- Respiratory viral infections research
- COVID-19 Digital Contact Tracing
- Animal Disease Management and Epidemiology
- Neonatal Respiratory Health Research
Emory University
2023-2025
Children's Healthcare of Atlanta
2023-2025
Yale University
2023-2025
Background: Secondhand smoke exposure (SHSe) is a public health threat for people with cystic fibrosis (CF) and other lung diseases. Primary smoking reduces CFTR channel function, the causative defect in CF. We reported that SHSe worsens respiratory nutritional outcomes CF by disrupting immune responses metabolic signaling. Recently, electronic cigarette (e-cigs) usage caregivers peers has increased rapidly, causing new secondhand e-cig vape exposures. vaping associated immunologic deficits...
Background CFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor–tezacaftor–ivacaftor (ETI) fails to improve innate immune signaling responsible for clearance resolution remains unknown. Methods We used an unbiased proteomics approach measure the effect of ETI on inflammatory proteins. Plasma from 20 pediatric pwCF non-CF (NCF) was collected during routine examination 3 months after...
Abstract Objectives Removal of zero-COVID restrictions in China led to a surge COVID-19 cases. In response, countries imposed on Chinese travelers. However, border policies may not provide substantial benefits and their assessment depends accurate prevalence data. Methods We analyzed quarantines testing sufficient prevent additional in-country transmission for February 13–19, 2023 based World Health Organization (WHO) self-reported infection rates estimate prevalence. Results Here we have...